Brown Rudnick represented  Edwards Lifesciences, the global leader in patient-focused medical innovations for structural heart disease, as well as critical care and surgical monitoring, in a strategic transaction with Corvia Medical, Inc. 

Edwards invested $35 million in an exclusive right to acquire Corvia Medical, the developer of the world's first transcatheter device designed to treat heart failure with preserved or mid-range ejection fraction. The Brown Rudnick team was led by partners Rob Funsten and Katy Gardner and included associates and Harrison Freeman. Support for the transaction was provided by partners Adam Cantor, Vince Guglielmotti and Nicole Bouchard (tax/employee benefits) and partner Mark Leonardo and associate Annie Kock (intellectual property).

FOR QUESTIONS OR MORE INFORMATION, PLEASE CONTACT:

Robert C. Funsten

P: +1.949.440.0216

F: +1.949.486.3645

Catherine (Katy) Gardner

P: +1.212.209.4922

F: +1.617.289.0691